MX2020003071A - Sistema de expresion de paramyxoviridae. - Google Patents
Sistema de expresion de paramyxoviridae.Info
- Publication number
- MX2020003071A MX2020003071A MX2020003071A MX2020003071A MX2020003071A MX 2020003071 A MX2020003071 A MX 2020003071A MX 2020003071 A MX2020003071 A MX 2020003071A MX 2020003071 A MX2020003071 A MX 2020003071A MX 2020003071 A MX2020003071 A MX 2020003071A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- paramyxoviridae
- interest
- expression system
- vectors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere al campo de vacunas (vector), y especialmente a una disposición mejorada de secuencias de nucleótidos para expresar un virus Paramyxoviridae que contiene un gen exógeno de interés. La presente invención además se refiere a casetes y vectores de expresión relacionados, que son adecuados para expresar genes de interés, en especial secuencias codificadoras de antígenos. Los vectores virales de la presente invención son útiles para producir una composición inmunogénica o vacuna.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17192791 | 2017-09-23 | ||
PCT/EP2018/075542 WO2019057859A1 (en) | 2017-09-23 | 2018-09-20 | EXPRESSION SYSTEM OF PARAMYXOVIRIDAE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003071A true MX2020003071A (es) | 2020-07-28 |
Family
ID=60019685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003071A MX2020003071A (es) | 2017-09-23 | 2018-09-20 | Sistema de expresion de paramyxoviridae. |
Country Status (17)
Country | Link |
---|---|
US (1) | US11730805B2 (es) |
EP (1) | EP3675903A1 (es) |
JP (1) | JP7038804B2 (es) |
KR (1) | KR20200057742A (es) |
CN (1) | CN111093698B (es) |
AR (1) | AR113124A1 (es) |
AU (1) | AU2018335252A1 (es) |
BR (1) | BR112020005767A2 (es) |
CA (1) | CA3072553A1 (es) |
CL (1) | CL2020000606A1 (es) |
EA (1) | EA202090628A1 (es) |
MX (1) | MX2020003071A (es) |
MY (1) | MY201967A (es) |
PH (1) | PH12020500526A1 (es) |
TW (1) | TW201923084A (es) |
UY (1) | UY37889A (es) |
WO (1) | WO2019057859A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3675903A1 (en) * | 2017-09-23 | 2020-07-08 | Boehringer Ingelheim Vetmedica GmbH | Paramyxoviridae expression system |
EP4126036A4 (en) * | 2020-03-27 | 2024-05-15 | Xuping Xie | REVERSE GENETIC SYSTEM FOR SARS-COV-2 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US382425A (en) | 1888-05-08 | Brandt | ||
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
IE872748L (en) | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JP3250802B2 (ja) | 1989-03-21 | 2002-01-28 | バイカル・インコーポレイテッド | 脊椎動物における外因性ポリヌクレオチド配列の発現 |
US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
JP3602530B2 (ja) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
IL108915A0 (en) | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
EP0740704A1 (en) | 1994-01-27 | 1996-11-06 | University Of Massachusetts Medical Center | Immunization by inoculation of dna transcription unit |
ES2243937T3 (es) | 1994-04-29 | 2005-12-01 | Baxter Healthcare S.A. | Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños. |
EP0871755A1 (en) | 1995-03-23 | 1998-10-21 | Cantab Pharmaceuticals Research Limited | Vectors for gene delivery |
AU737243B2 (en) | 1996-07-03 | 2001-08-16 | Merial, Inc. | Recombinant canine adenovirus (CAV) containing exogenous DNA |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US20030224017A1 (en) * | 2002-03-06 | 2003-12-04 | Samal Siba K. | Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors |
BR0112384A (pt) | 2000-06-23 | 2003-09-23 | American Cyanamid Co | Recuperação do vìrus da cinomose partindo do cdna |
ES2358849T3 (es) | 2006-03-15 | 2011-05-16 | Intervet International Bv | Vectores de virus mononegavirales recombinantes. |
KR20080103602A (ko) | 2006-03-15 | 2008-11-27 | 인터벳 인터내셔널 비.브이. | 재조합 모노네가바이랄러스 바이러스 벡터 |
US20110027308A1 (en) | 2007-09-10 | 2011-02-03 | Intervet International B.V. | Compositions and methods for preventing influenza infection in canines, felines and equines |
CA2724908C (en) | 2008-07-23 | 2017-03-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hgh polyadenylation signal |
WO2010036948A2 (en) * | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
SG11201702997YA (en) | 2014-11-04 | 2017-05-30 | Janssen Vaccines & Prevention Bv | Therapeutic hpv16 vaccines |
MX2018002106A (es) | 2015-08-20 | 2018-06-15 | Janssen Vaccines & Prevention Bv | Vacunas terapeuticas contra el hpv18. |
EP3353192A4 (en) | 2015-09-21 | 2019-05-15 | Oregon Health and Science University | DESIGN AND CHARACTERIZATION OF INFLUENZA VACCINES |
CN108601823A (zh) | 2015-09-23 | 2018-09-28 | 麻省理工学院 | 用于改性树枝状聚合物纳米颗粒疫苗递送的组合物和方法 |
PT3355915T (pt) | 2015-09-29 | 2023-12-19 | Boehringer Ingelheim Animal Health Usa Inc | Vacinas de partículas pseudovirais (vlp) de parvovírus canino (cpv) e suas utilizações |
EP3675903A1 (en) * | 2017-09-23 | 2020-07-08 | Boehringer Ingelheim Vetmedica GmbH | Paramyxoviridae expression system |
TW202026010A (zh) * | 2018-09-20 | 2020-07-16 | 德商百靈佳殷格翰維美迪加股份有限公司 | 抗豬流行性下痢之鼻內載體疫苗 |
-
2018
- 2018-09-20 EP EP18769224.9A patent/EP3675903A1/en active Pending
- 2018-09-20 MY MYPI2020000875A patent/MY201967A/en unknown
- 2018-09-20 EA EA202090628A patent/EA202090628A1/ru unknown
- 2018-09-20 US US16/649,456 patent/US11730805B2/en active Active
- 2018-09-20 AU AU2018335252A patent/AU2018335252A1/en not_active Abandoned
- 2018-09-20 MX MX2020003071A patent/MX2020003071A/es unknown
- 2018-09-20 CA CA3072553A patent/CA3072553A1/en active Pending
- 2018-09-20 JP JP2020516567A patent/JP7038804B2/ja active Active
- 2018-09-20 CN CN201880059912.2A patent/CN111093698B/zh active Active
- 2018-09-20 AR ARP180102699A patent/AR113124A1/es unknown
- 2018-09-20 BR BR112020005767-3A patent/BR112020005767A2/pt unknown
- 2018-09-20 KR KR1020207011578A patent/KR20200057742A/ko active Search and Examination
- 2018-09-20 UY UY0001037889A patent/UY37889A/es unknown
- 2018-09-20 TW TW107133155A patent/TW201923084A/zh unknown
- 2018-09-20 WO PCT/EP2018/075542 patent/WO2019057859A1/en active Search and Examination
-
2020
- 2020-03-10 CL CL2020000606A patent/CL2020000606A1/es unknown
- 2020-03-13 PH PH12020500526A patent/PH12020500526A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018335252A1 (en) | 2020-02-27 |
MY201967A (en) | 2024-03-27 |
PH12020500526A1 (en) | 2021-03-15 |
EA202090628A1 (ru) | 2020-11-16 |
TW201923084A (zh) | 2019-06-16 |
UY37889A (es) | 2019-03-29 |
CN111093698B (zh) | 2024-04-05 |
JP2020537507A (ja) | 2020-12-24 |
US20200276298A1 (en) | 2020-09-03 |
CN111093698A (zh) | 2020-05-01 |
JP7038804B2 (ja) | 2022-03-18 |
AR113124A1 (es) | 2020-01-29 |
CL2020000606A1 (es) | 2020-08-21 |
KR20200057742A (ko) | 2020-05-26 |
CA3072553A1 (en) | 2019-03-28 |
BR112020005767A2 (pt) | 2020-10-13 |
US11730805B2 (en) | 2023-08-22 |
WO2019057859A1 (en) | 2019-03-28 |
EP3675903A1 (en) | 2020-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
CY1121528T1 (el) | Ανασυνδυασμενοι φορεις ερπητοϊου gallid 3 (mdv οροτυπου 2) που εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων | |
PH12019500557A1 (en) | New ehv insertion site orf70 | |
PH12019501130A1 (en) | Viral delivery of neoantigens | |
MX2019004499A (es) | Sistemas de replicón de virus recombinante y usos de estos. | |
PH12019500578A1 (en) | New promoters | |
PH12019500591A1 (en) | Canine adenovirus vectors | |
MX2012008651A (es) | Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas. | |
MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
AR071910A1 (es) | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. | |
PH12020500526A1 (en) | Paramyxoviridae expression system | |
AR101840A1 (es) | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene | |
NZ759538A (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
PH12020551442A1 (en) | New ehv with inactivated ul18 and/or ul8 | |
MX338052B (es) | Vectores de parapoxvirus que contienen el antigeno del virus de la rabia. | |
MX2018000353A (es) | Sistema vector de adenovirus aviar 9 (fadv-9) y metodos asociados. | |
MX2020001655A (es) | Vacuna vph. | |
MX2019007924A (es) | Vacunas contra la influenza. | |
MX2020009722A (es) | Nuevo sitio de insercion ul43 de ehv. | |
NZ703070A (en) | Recombinant low virulence bovine herpesvirus 1 (bohv-1) vaccine vectors |